CROSSJECT Aktie

>CROSSJECT Aktienkurs

2.048 EUR (TradegateBSX)

Ask: 2.065 EUR / 540 Stück

Bid: 2.03 EUR / 550 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CROSSJECT Aktie über LYNX handeln

Intraday

1 Jahr

>CROSSJECT Performance

1 Woche: +3,8%

1 Monat: -0,1%

3 Monate: -4,8%

6 Monate: +2,5%

1 Jahr: +92,4%

laufendes Jahr: -6,5%

>CROSSJECT Aktie

Name:

CROSSJECT SA EO -,10

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0011716265 / A1XEH4

Symbol/ Ticker:

74C (Frankfurt)

Kürzel:

FRA:74C, ETR:74C, 74C:GR

Index:

Webseite:

https://www.crossject.com..

Profil:

Crossject S.A. is a pharmaceutical company specializing in the development of needle-free, pre-filled delivery systems known as Zeneo injectors. Its primary function is to provide a pain-free, user-friendly alternative to traditional hypodermic injec..
>Volltext..

Marktkapitalisierung:

109.59 Mio. EUR

Unternehmenswert:

124.33 Mio. EUR

Umsatz:

EBITDA:

3.8 Mio. EUR

Nettogewinn:

-10.55 Mio. EUR

Gewinn je Aktie:

-0.21 EUR

Schulden:

20.16 Mio. EUR

Liquide Mittel:

5.17 Mio. EUR

Operativer Cashflow:

Bargeldquote:

0.77

Umsatzwachstum:

Gewinnwachstum:

18.98%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CROSSJECT

Letzte Datenerhebung:

06.04.26

>CROSSJECT Kennzahlen

Aktien/ Unternehmen:

Aktien: 52.72 Mio. St.

Frei handelbar: 64.87%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 116.05%

Bewertung:

KGV: -

KGV lG: 9.35

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: 32.75

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -33.44%

Eigenkaprendite: -

>CROSSJECT Peer Group

Gesundheit

>CROSSJECT Chart & Kurs - Tradegate

>CROSSJECT News

25.03.26 - 18:03	CROSSJECT appoints Lionel Seltz as Chief Financial Officer (GlobeNewswire EN)
	DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto-injector platform, notably ZEPIZURE® for the emergency treatment of epileptic seizures, today announces the appointment of Lionel Seltz as Chief Financial Officer....

25.03.26 - 07:24

CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory (GlobeNewswire EN)

DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, currently in the advanced stages of development and registration of ZEPIZURE®, an injectable for the management of epileptic seizures, today publishes its financial results for the financial year ended 31 December 2025....

02.02.26 - 07:18	CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) (GlobeNewswire EN)
	CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)...

14.11.25 - 20:48	CROSSJECT completes €5 million financing with Vatel Capital (GlobeNewswire EN)
	Press release...

24.09.25 - 22:03	CROSSJECT presents its financial results and key highlights for the first half of 2025 (GlobeNewswire EN)
	Press release...

22.09.25 - 07:33	CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) (GlobeNewswire EN)
	Press release...

04.08.25 - 17:39	CROSSJECT remains engaged during the summer break (GlobeNewswire EN)
	Press Release...

24.06.25 - 19:03	CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause (GlobeNewswire EN)
	Press release...

11.06.25 - 07:33	CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children (GlobeNewswire EN)
	Press release...

03.06.25 - 07:33	Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 (GlobeNewswire EN)
	Press release...

27.05.25 - 07:33	CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ′s versatility and capacity in anticipation of full product pipeline deployment (GlobeNewswire EN)
	Press release...

20.05.25 - 07:33	CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval (GlobeNewswire EN)
	Press Release...

15.05.25 - 07:33	CROSSJECT′s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors (GlobeNewswire EN)
	Press Release...

07.05.25 - 07:33	CROSSJECT provides updates on the EUA filing of ZEPIZURE® (GlobeNewswire EN)
	Press Release...

27.03.25 - 07:33	CROSSJECT reports financial results for 2024 (GlobeNewswire EN)
	Press Release...

25.03.25 - 07:33	CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program (GlobeNewswire EN)
	Press Release...

18.03.25 - 17:39	CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones (GlobeNewswire EN)
	Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram